GlassScriptPhysician profile
Sultan Yusufzai
NPI 1831479815
$13,229.34
in general payments reported to CMS, 2019-2025
59 companies · $2,668 in 2025
The $2,668 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $630 · 2020: $806 · 2021: $1,148 · 2022: $2,647 · 2023: $2,818 · 2024: $2,512 · 2025: $2,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,998.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,978.94 | 2021-2025 | Ubrelvy, Qulipta, Linzess |
| Glaxosmithkline, LLC. | $1,802.32 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,073.87 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,029.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $915.03 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $579.28 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $544.02 | 2023-2025 | Xywav |
| Novartis Pharmaceuticals Corporation | $452.32 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $435.54 | 2021-2025 | Jardiance |
| Amgen INC. | $385.36 | 2022-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $352.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Aimmune Therapeutics, INC. | $351.66 | 2024-2025 | Zenpep, Vowst |
| Pfizer INC. | $286.62 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $266.79 | 2019-2024 | Xifaxan |
| Amarin Pharma, INC. | $195.84 | 2019-2022 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sultan Yusufzai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.